Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals

Mirum Pharmaceuticals Acquires Bluejay Therapeutics

January 26, 2026

Pharmaceuticals

Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, adding brelovitug — a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV) — to its rare liver disease pipeline. The deal gives Mirum worldwide rights to the AZURE Phase 3 program and includes a combination of cash and Mirum common stock with potential sales‑based milestone payments; Mirum also raised approximately $268.5M in concurrent financing to support development and commercialization.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.

Regeneron Acquires Checkmate Pharmaceuticals

April 19, 2022

Biotechnology

Regeneron Pharmaceuticals agreed to acquire Checkmate Pharmaceuticals in an all-cash transaction valuing Checkmate at approximately $250 million (at $10.50 per share). The acquisition brings Checkmate's lead investigational immune activator, vidutolimod (a VLP-delivered TLR9 agonist), into Regeneron’s immuno-oncology portfolio to accelerate development and enable combination strategies across tumor types.

Merck to Acquire Imago BioSciences, Inc.

November 21, 2022

Pharmaceuticals

Merck has agreed to acquire clinical-stage biopharmaceutical company Imago BioSciences for $36.00 per share, representing an approximate equity value of $1.35 billion. The acquisition adds Imago's lead LSD1 inhibitor bomedemstat to Merck's hematology pipeline and is expected to close after a tender offer and customary regulatory clearances in early 2023.

Vistagen Acquires Pherin Pharmaceuticals

December 21, 2022

Biotechnology

Vistagen (Nasdaq: VTGN) will acquire Pherin Pharmaceuticals in an all-stock transaction (approximately 12.4 million shares plus nominal cash), giving Vistagen full ownership of Pherin's pherine drug pipeline and intellectual property. The deal eliminates future royalty and milestone obligations related to PH94B and PH10 and adds three early-stage pherine candidates to Vistagen's development portfolio.

Eli Lilly Acquires Morphic

July 8, 2024

Biotechnology

Eli Lilly agreed to acquire Morphic Holding, Inc. for $57 per share (approximately $3.2 billion) to expand its immunology and gastroenterology pipeline with Morphic's oral integrin therapies, including MORF-057. Lilly commenced a tender offer that was completed (with subsequent second-step merger) and the transaction closed in August 2024.